UroGen Pharma (URGN) Insider JR. Buys 10,000 Shares
Robinson James JR. purchased 10,000 shares of UroGen Pharma Ltd. on June 22, 2026, amid increased insider buying activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Robinson James JR. bought 10,000 shares of UroGen Pharma Ltd. ($URGN) on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $URGN is up 3.1% after 1 week, up 20.2% after 1 month and down 1.2% to date (from the $34.99 close on Jun 22, 2026).
URGN
UroGen Pharma Ltd.
Key Points
- Robinson James JR. bought 10,000 shares of URGN on June 22, 2026, with the stock priced at $35.58 at the time of the trade.
- UroGen Pharma Ltd. has seen significant insider buying recently, including purchases from Stuart Holden and Leana Wen on the same day.
- Analysts maintain a strong buy outlook for URGN, with a mean price target of $60.00 following recent upgrades.
Get $URGN trade alerts by text
We text you when insiders, Congress or big funds trade $URGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated UroGen Pharma Ltd. alert may contain errors. Disclosures
Insider Buying and Selling at UroGen Pharma Ltd.
Robinson James JR. bought 10,000 shares of UroGen Pharma Ltd. (NasdaqGM: URGN) on June 22, 2026. The stock was trading at $35.58 at the time of the purchase. This acquisition adds to a wave of insider buying, suggesting a positive outlook among company executives.
Recent Insider Trades
Stuart Holden also acquired 20,000 shares on June 22, 2026, showing strong interest from insiders. Additionally, Leana Wen purchased 10,000 shares on the same day. Other notable trades included Wildman Daniel George and Cynthia Butitta, each buying 10,000 shares, while Chief Medical Officer Mark Schoenberg sold 10,000 shares at $35.01, valued at $350,100. This activity reflects a trend of increased insider buying at UroGen Pharma.
Stock Performance and Market Context
UroGen Pharma's stock is currently trading at $35.58, significantly below its 52-week high of $50.81 and above its low of $15.86. The stock's recent performance may be influenced by insider transactions and analyst ratings that suggest potential growth. The company has a forward P/E ratio of 15.46, indicating that analysts expect it to become profitable as it continues to develop its cancer treatment pipeline.
Analysts Set New Price Targets
On August 6, 2026, Guggenheim maintained a "Buy" rating with a price target of $58.00, up from $42.00. Similarly, HC Wainwright & Co. also maintained a "Buy" rating with a target of $75.00. TD Cowen kept a "Buy" rating with a target of $60.00, reflecting strong confidence in UroGen's future performance. The average target among analysts is $60.00, with a consensus recommendation of "strong buy."
What URGN Does
UroGen Pharma Ltd. focuses on developing treatments for urothelial and specialty cancers. Its pipeline includes innovative therapies like RTGel and Jelmyto, aimed at improving patient outcomes in cancer care. The recent insider buying highlights the confidence executives have in the company’s future prospects as it advances its clinical trials.
What's Ahead for URGN
Investors will be watching for UroGen's next earnings report, scheduled for November 5, 2026. This insider buying activity and the positive analyst outlook suggest that the company is positioning itself well for future growth. Note that this insider trading information reflects past transactions and may not indicate current positions.
Related Filing Alerts
Source: Robinson James JR.'s Form 4 filing on $URGN (Jun 22, 2026). Find the original filing: URGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts